Poseida Therapeutics and Rapha Capital Management Rapha Capital Management Participates in Series D Financing for Poseida Therapeutics June 25, 2020
Read More
Asclepix Therapeutics, Inc. Better than Eylea, as durable as gene therapy? Perceptive, Xontogeny boost ophthalmic startup’s shot for best of all worlds Amber Tong, Editor, ENDPOINTS NEWS June 24, 2020
Asclepix Therapeutics, Inc. AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis Frank Vinluan, Editor, Xconomy June 24, 2020
Asclepix Therapeutics, Inc. AsclepiX Therapeutics Announces $35 Million Series A Financing Proceeds to fund development of AXT107 for treatment of retinal diseases through Phase 1/2a clinical trials Series A financing…
Poseida Therapeutics, Inc. Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer May 20, 2020
FIZE Medical Ltd. Rapha Capital Management Leads Series A Financing for FIZE Medical Ltd FIZE’s Novel Device Conquers the Last Frontier in Patient Monitoring May 4, 2020
Asclepix Therapeutics, Inc. AsclepiX Therapeutics, Inc. Expands Leadership Team with Appointment of Industry Leader Theresa Heah, MD, MBA as Chief Medical Officer January 6, 2020
ControlRad, Inc. ControlRad Adds Five People to Leadership Team December 17, 2019
NexImmune Inc. NexImmune Appoints Sol Barer as Chairman of the Board of Directors December 16, 2019
3D Bio Therapeutics, Inc. 3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients December 6, 2019